CRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month Low - Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price reached a new 52-week low on Monday . The stock traded as low as $30.04 and last traded at $30.33, with a volume of 327556 shares. The stock had previously closed at $32.65.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent research reports. Barclays boosted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Bank of America decreased their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their target price for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Finally, The Goldman Sachs Group dropped their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Price Performance

The business's fifty day moving average price is $41.14 and its 200 day moving average price is $44.03. The stock has a market cap of $3.37 billion, a P/E ratio of -8.99 and a beta of 1.85.

Remove Ads

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wood Tarver Financial Group LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $30,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $36,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $40,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.